Selarsdi, ustekinumab-aekn (biosimilar to Stelara)
Named-patient access overview. Selarsdi is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Selarsdi
Selarsdi (ustekinumab-aekn) is a biosimilar to Stelara, developed by Alvotech and commercialized in the United States by Teva Pharmaceuticals. It was approved by the US FDA in 2024 for moderate-to-severe plaque psoriasis in adults and pediatric patients six years and older, and for active psoriatic arthritis in adults, following the reference product's approved indication scope.
The molecule is a fully human monoclonal antibody that binds the shared p40 subunit of interleukin-12 and interleukin-23, blocking downstream signaling on T cells, NK cells, and antigen-presenting cells implicated in psoriatic inflammation. Selarsdi is administered subcutaneously, typically with a loading regimen followed by maintenance dosing every twelve weeks.
Selarsdi may be accessible to international patients through Named Patient Program or personal-import pathways. As a biosimilar to Stelara, it is indicated within the reference product's approved scope and is not a novel molecule.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Selarsdi
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Selarsdi for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Selarsdi is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Selarsdi in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Selarsdi
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.